Thomas MacDonald

Academic, Clinical Professor (Teaching and Research) of Clin Pharma and Pharmacoepidemiology

University of Dundee

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Thomas MacDonald is a Clinical Professor (Teaching and Research) of Clinical Pharmacy and Pharmacoepidemiology at the University of Dundee, UK. His research areas include hypertension management, cardiovascular outcomes related to antihypertensives, and the genetic factors influencing gout. Recent publications highlight his work on blood pressure management and the implications of digital platforms in decentralized clinical trials.

Articles (21)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (22)

Michał Dobrakowski

Medical University of Silesia

POLAND

Thomas MacDonald

Research Interests

Explore related searches

Contact this professor

About

Articles (21)

Professor Alan G. Jardine: 27th August 1960–3rd April 2025, aged 64

Low Achieved Systolic Blood Pressure Related to Kidney Protection in Diabetic and Non-Diabetic High-Risk Hypertensive Patients

Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension

UMOD Genotype-Blinded Trial of Ambulatory Blood Pressure Response to Torasemide

The Digital Platform and Its Emerging Role in Decentralized Clinical Trials

Effect of timed dosing of usual antihypertensives according to patient chronotype on cardiovascular outcomes

Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease

A genome-wide association analysis reveals new pathogenic pathways in gout

Vascular and inflammatory biomarkers of cardiovascular events in non-steroidal anti-inflammatory drug users

Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors: analysis of LIPIDOGRAM2015 and LIPIDOGEN2015 studies

Impact of beta-blockers on mortality and cardiovascular disease outcomes in patients with obstructive sleep apnoea

Metabolic syndrome is associated with similar long-term prognosis in those living with and without obesity: an analysis of 45 615 patients from the nationwide LIPIDOGRAM 2004–2015 studies

Obituary

Cardiovascular safety in type 2 diabetes with sulfonylureas as second-line drugs

Reply to 'Evening or morning dosing of antihypertensive medications

Diagnosis and management of primary hyperaldosteronism in patients with hypertension: a practical approach endorsed by the British and Irish Hypertension Society

Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME Study)

Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART)

Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT)

A first step towards best practice recommendations for the design and statistical analyses of pragmatic clinical trials

Bedtime dosing of antihypertensive medications

Collaborators (22)

Michał Dobrakowski

Tadeusz Osadnik

Jaspal S Taggar

Isla Mackenzie

Hongbo Liu

Amy Rogers

Allan Struthers

Murray Donald Smith

Huan Wang

Alex McConnachie

Fernando Perez-Ruiz

Alexander Doney

Li Wei

Mary Joan Macleod

Sten Hanke

Peter Penson

Maciej Tomaszewski

Riku Takei

Rory J. McCrimmon

Colin J. Crooks

Marek Gierlotka

Maciej Banach

Make your next move.